ClinicalTrials.gg
CompletedNCT06384131Updated Jul 23, 2025

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection

A Phase 1 interventional study of ABI-4334 and Placebo in Chronic Hepatitis B, sponsored by Assembly Biosciences. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Assembly Biosciences · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Hepatitis B, Chronic by Assembly Biosciences — none open to participants now, none under way, none of them phase 3. Hepatitis B, Chronic · Assembly Biosciences.

Enrollment
14th of 17
20 · median 54
Started
2024
the only one that year
Phase 1
9 of 17
none open now
Registered
17th of 17
by date

Among the 17 studies in Hepatitis B, Chronic by Assembly Biosciences, this one is the 14th largest by enrollment, is the only one that started in 2024, is one of 9 in phase 1, and was the 17th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 17 studies in Hepatitis B, Chronic by Assembly Biosciences is open now. The open studies under Hepatitis B, Chronic, anywhere →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Hepatitis B, Chronic by Assembly Biosciences as a file.
02

Study summary

This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-4334 or placebo.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • cHBV
  • HBV
  • Hepatitis B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ≥ 18.0 and \< 35.0 kg/m(2), where BMI = weight (kg)/(height [m])(2) with a minimum body weight of 45 kg
  2. Chronic infection, defined as HBV infection for ≥ 6 months documented
  3. Treatment-naïve or off-antiviral therapy for ≥ 24 weeks prior to Screening
  4. Lack of bridging fibrosis or cirrhosis

Exclusion criteria

Exclusion Criteria:

  1. Co-infection with (HIV), virus (HCV), hepatitis D virus (HDV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV)
  2. History of liver transplant or evidence of advanced liver disease, cirrhosis, or hepatic decompensation
  3. diseases or conditions
  4. History of hepatocellular carcinoma
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    ABI-4334

    Drug: ABI-4334

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugABI-4334

    10 mg or 50 mg tablets for oral administration

  • DrugPlacebo

    10 mg or 50 mg tablets for oral administration

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of ABI-4334 in subjects with cHBV following 28-day multiple oral doses

    Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs, and abnormal laboratory results

    Time frame: Through end of study, up to 56 days

Secondary outcomes

  1. To characterize the PK of ABI-4334 in plasma following 28-day multiple doses in subjects with cHBV

    Noncompartmental plasma PK parameters

    Time frame: Through treatment period, up to 28 days

  2. Changes in HBV DNA in subjects with cHBV following 28-day multiple doses of ABI-4334

    Mean change in log10 HBV DNA between Baseline and Day 28

    Time frame: Through treatment period, up to 28 days

  3. To characterize the PK of ABI-4334 in plasma following 28-day multiple doses in subjects with cHBV

    Area Under Plasma Concentration-Time Curve (AUC) of ABI-4334 in subjects with cHBV

    Time frame: Through treatment period, up to 28 days

  4. To characterize the PK of ABI-4334 in plasma following 28-day multiple doses in subjects with cHBV

    Time to Maximum Plasma Concentration (Tmax) of ABI-4334 in subjects with cHBV

    Time frame: Through treatment period, up to 28 days

  5. Elimination half-life (t1/2) of ABI-4334 in subjects with cHBV

    Time frame: Through treatment period, up to 28 days

  6. Changes in HBV pregenomic ribonucleic acid (pgRNA) and additional markers of antiviral activity in subjects with cHBV

    To evaluate the changes in HBV DNA (IU/mL or Log IU/mL) in subjects with cHBV

    Time frame: Through treatment period, up to 28 days

  7. Changes in HBV DNA in subjects with cHBV following 28-day multiple doses of ABI-4334

    Proportion of subjects with HBV DNA \< lower limit of quantification (LLOQ) and/or limit of detection (LOD)

    Time frame: Through treatment period, up to 28 days

  8. Changes in HBV DNA in subjects with cHBV following 28-day multiple doses of ABI-4334

    Mean time elapsed to subjects achieving HBV DNA \< LLOQ and/or LOD

    Time frame: Through treatment period, up to 28 days

07

Study locations

2 sites
  • ARENSIA Exploratory Medicine Chisinau
    Chisinau, Moldova
  • New Zealand Clinical Research
    Auckland, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Apr 2025, 10 months.

Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Jun 4, 2024
Primary completionActual
Apr 15, 2025
CompletionActual
May 14, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06384131
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Jun 4, 2024
Primary completion
Apr 15, 2025
Completion
May 14, 2025
Last update
Jul 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion